Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jan 13, 2014
Insider Transaction Report
Form 4
Mirovsky Pavel
President of Valeant Europe
Transactions
- Award
Restricted Share Units
2014-01-09+24,175→ 24,175 totalExercise: $0.00→ Common Shares, no par value (24,175 underlying)
Footnotes (2)
- [F1]Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $108.97 on each of three measurement dates: 25% would vest on October 9, 2016, 50% on January 9, 2017 and 25% on April 9, 2017, with early vesting possible at higher TSR levels.